,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2004', 'fs': 'Dec 2004', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW23UAE'}, 'Id': 'a0P2P000006hW23UAE', 'Event_Date__c': '2004-12-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Dec 2004', 'Status_History__c': 'a132P000000Ap1CQAS'}, 'change': None}]",Dec 2004,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2004', 'fs': 'Dec 2004', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW24UAE'}, 'Id': 'a0P2P000006hW24UAE', 'Event_Date__c': '2004-12-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Dec 2004', 'Status_History__c': 'a132P000000Ap1EQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Deferred', 'fs': 'Deferred', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2005', 'fs': 'Mar 2005', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 10 March 2005.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 10 March 2005.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW26UAE'}, 'Id': 'a0P2P000006hW26UAE', 'Event_Date__c': '2005-03-10', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Thursday 10 March 2005.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Deferred', 'Formatted_Date__c': 'Mar 2005', 'Status_History__c': 'a132P000000Ap2GQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2005', 'fs': 'Aug 2005', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW27UAE'}, 'Id': 'a0P2P000006hW27UAE', 'Event_Date__c': '2005-08-01', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Aug 2005', 'Status_History__c': 'a132P000000Ap3lQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2005', 'fs': 'Sep 2005', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 2 September 2005.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 2 September 2005.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW28UAE'}, 'Id': 'a0P2P000006hW28UAE', 'Event_Date__c': '2005-09-02', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 2 September 2005.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Sep 2005', 'Status_History__c': 'a132P000000Ap4PQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2006', 'fs': 'Apr 2006', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW29UAE'}, 'Id': 'a0P2P000006hW29UAE', 'Event_Date__c': '2006-04-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Apr 2006', 'Status_History__c': 'a132P000000Ap6BQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'fs': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2006', 'fs': 'Apr 2006', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Wednesday 19 April 2006.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Wednesday 19 April 2006.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2AUAU'}, 'Id': 'a0P2P000006hW2AUAU', 'Event_Date__c': '2006-04-19', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Wednesday 19 April 2006.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Apr 2006', 'PTAC_Comments__c': 'These minutes have been ratified by the Pharmacology and Therapeutic Advisory Committee.', 'Status_History__c': 'a132P000000Ap6HQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2006-05.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2006-05.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2006', 'fs': 'May 2006', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 24 May 2006.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 24 May 2006.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2BUAU'}, 'Id': 'a0P2P000006hW2BUAU', 'Event_Date__c': '2006-05-24', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Wednesday 24 May 2006.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2006-05.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2006', 'Status_History__c': 'a132P000000Ap6iQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2EUAU'}, 'Id': 'a0P2P000006hW2EUAU', 'Event_Date__c': '2013-02-28', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqLFQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2013', 'fs': 'May 2013', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2FUAU'}, 'Id': 'a0P2P000006hW2FUAU', 'Event_Date__c': '2013-05-09', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 9 May 2013.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2013-05.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'May 2013', 'Status_History__c': 'a132P000000AqPJQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2IUAU'}, 'Id': 'a0P2P000006hW2IUAU', 'Event_Date__c': '2020-02-27', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2020', 'Status_History__c': 'a132P000000BVd1QAG'}, 'change': None}, {'Summary': {'s': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee recommended that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be declined.</span></p>', 'fs': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee recommended that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be declined.</span></p>', 'change': None}, 'Published_Recommendation': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be <b>declined</b>.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be <b>declined</b>.</p>', 'change': None}, 'Published_Discussion': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p>', 'change': None}, 'Published_Application': {'s': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a funding application from the Gastrointestinal Tumour Specialist Interest Group for bevacizumab for the first- and second-line treatment of metastatic colorectal cancer.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed correspondence from the Gastrointestinal Tumour Specialist Interest Group, which provided an overview of the treatment landscape for colorectal cancer.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a funding application from the Gastrointestinal Tumour Specialist Interest Group for bevacizumab for the first- and second-line treatment of metastatic colorectal cancer.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed correspondence from the Gastrointestinal Tumour Specialist Interest Group, which provided an overview of the treatment landscape for colorectal cancer.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">Cancer Treatment Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">Cancer Treatment Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2020', 'fs': 'Feb 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'fs': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2JUAU'}, 'Id': 'a0P2P000006hW2JUAU', 'Event_Date__c': '2020-02-27', 'Event_Description__c': 'Clinical advice received from Cancer Treatments Subcommittee (CaTSoP) at meeting Friday 5 July 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-cancer-treatment-subcommittee-record-2019-07.pdf"" target=""_blank"">Cancer Treatment Subcommittee minutes</a></p>', 'Outcome__c': 'Decline', 'Summary__c': '<p><span style=""font-family: Arial, sans-serif; font-size: 11pt;"">The Subcommittee recommended that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be declined.</span></p>', 'Formatted_Date__c': 'Feb 2020', 'Published_Recommendation__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee <b>recommended</b> that bevacizumab for the first- and second-line treatment of metastatic colorectal cancer be <b>declined</b>.</p>', 'Published_Application__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed a funding application from the Gastrointestinal Tumour Specialist Interest Group for bevacizumab for the first- and second-line treatment of metastatic colorectal cancer.</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee reviewed correspondence from the Gastrointestinal Tumour Specialist Interest Group, which provided an overview of the treatment landscape for colorectal cancer.</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee took into account, where applicable, PHARMAC’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p><p><span style=""color: black;"">1.1.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the application for cetuximab for the first-line treatment of RAS wild-type, left-sided metastatic colorectal cancer (mCRC) was reviewed by PTAC in <a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2018-08.pdf"" target=""_blank"">August 2018</a>. At this time, PTAC recommended that cetuximab be declined and referred the application to CaTSoP for advice regarding EGFR-inhibition in mCRC (including for anatomically defined sub-populations).</p><p><span style=""color: black;"">1.2.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that colorectal cancer is an area of high health need in New Zealand. The Subcommittee noted that there are 3000 new cases of colorectal cancer diagnosed each year in New Zealand and that approximately 20% of individuals present with metastatic disease. The Subcommittee noted that data from the United States Surveillance, Epidemiology, and End Results (SEER) program indicating mCRC 5-year survival of 14%. The Subcommittee noted that Māori and Pacific Peoples are diagnosed at younger ages, are more likely to have metastatic disease at diagnosis, and are more likely to have left-sided colorectal cancer (<a href=""http://www.hrc.govt.nz/sites/default/files/THE%20PIPER%20PROJECT%20Final%20deliverable%20report%207%20August%202015%20%28HRC%2011_764%20FINDLAY%29.pdf"" target=""_blank"">Jackson et al. The PIPER project final report. 2015</a>).</p><p><span style=""color: black;"">1.3.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the left and right side of the colon are derived from different embryologic origins, and that left- and right-sided colorectal cancers exhibit differences in incidence, pathogenesis, genetic and molecular signatures, and immunological profile. The Subcommittee noted that primary tumour location, or ‘sidedness’ has been recognised as a prognostic factor in mCRC for some time, but that it has only recently been suggested that ‘sidedness’ may also be predictive of response to treatment (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/27907852"" target=""_blank"">Holch et al. Eur J Cancer. 2017;70:87-98)</a>.</p><p><span style=""color: black;"">1.4.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that mutations in EGFR, RAS, and BRAF are widely accepted as prognostic and predictive markers in colorectal cancer. The Subcommittee considered that testing for EGFR is not normally conducted in New Zealand as it is assumed that most patients with CRC overexpress EGFR. The Subcommittee considered that access to RAS and BRAF testing in New Zealand is highly variable depending on region and that should eligibility for funding be determined in part by the presence or absence or mutations it would be important for this to be accompanied by an equitable approach to access to mutation testing across the country.</p><p><span style=""color: black;"">1.5.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that chemotherapy is the standard of care for patients with mCRC for whom surgery is not adequate or appropriate. The Subcommittee noted that single-agent chemotherapies used for mCRC include capecitabine and 5-fluorouracil and combination regimens include FOLFIRI (leucovorin + 5-fluorouracil + irinotecan), FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin), and XELOX (capecitabine + oxaliplatin).</p><p><span style=""color: black;"">1.6.</span><span style=""color: black; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The Subcommittee noted that the treatment paradigm suggested by the Gastrointestinal Tumour Specialist Interest Group and the applications being reviewed propose that cetuximab plus chemotherapy should be used for the first-line treatment of RAS wild-type, left-sided mCRC; bevacizumab plus chemotherapy should be used for the first-line treatment of RAS wild-type, right-sided mCRC and first-line treatment for all RAS mutant mCRC; and bevacizumab plus chemotherapy should be used for the second line treatment of all mCRC.</p>', 'Status_History__c': 'a132P000000BVeqQAG'}, 'change': None}]",Dec 2004,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2KUAU'}, 'Id': 'a0P2P000006hW2KUAU', 'Event_Date__c': '2021-04-23', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000Cn4uQAC'}, 'change': None}]",Apr 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2005', 'fs': 'Mar 2005', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW25UAE'}, 'Id': 'a0P2P000006hW25UAE', 'Event_Date__c': '2005-03-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2005', 'Status_History__c': 'a132P000000Ap27QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2GUAU'}, 'Id': 'a0P2P000006hW2GUAU', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqWZQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2HUAU'}, 'Id': 'a0P2P000006hW2HUAU', 'Event_Date__c': '2018-09-21', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXnQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2LUAU'}, 'Id': 'a0P2P000006hW2LUAU', 'Event_Date__c': '2021-06-25', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CxMfQAK'}, 'change': None}]",Mar 2005,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2MUAU'}, 'Id': 'a0P2P000006hW2MUAU', 'Event_Date__c': '2021-06-29', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CxtBQAS'}, 'change': None}]",Jun 2021,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2NUAU'}, 'Id': 'a0P2P000006hW2NUAU', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000D3w5QAC'}, 'change': None}]",Aug 2021,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2012', 'fs': 'Aug 2012', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2CUAU'}, 'Id': 'a0P2P000006hW2CUAU', 'Event_Date__c': '2012-08-01', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Formatted_Date__c': 'Aug 2012', 'Status_History__c': 'a132P000000Aq52QAC'}, 'change': None}, {'Summary': {'s': 'The supplier updated and resubmitted its application.', 'fs': 'The supplier updated and resubmitted its application.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2013', 'fs': 'Feb 2013', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2DUAU'}, 'Id': 'a0P2P000006hW2DUAU', 'Event_Date__c': '2013-02-01', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Decision', 'Summary__c': 'The supplier updated and resubmitted its application.', 'Formatted_Date__c': 'Feb 2013', 'Status_History__c': 'a132P000000AqIZQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hW2OUAU'}, 'Id': 'a0P2P000006hW2OUAU', 'Event_Date__c': '2022-02-04', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000Da6sQAC'}, 'change': None}]",Aug 2012,False,True
